Is renal medullary carcinoma the seventh nephropathy in sickle cell disease? A multi-center Nigerian survey

IntroductionPrevious studies had enlisted renal medullary carcinoma (RMC) as the seventh nephropathy in sickle cell disease (SCD). Clinical experience has contradicted this claim and this study is targeted at refuting or supporting this assumption.ObjectiveTo estimate the prevalence of RMC and describe other renal complications in SCD.ResultsOf the 3,596 registered sickle patients, 2 (0.056%) had been diagnosed with RMC over a ten year period, thereby giving an estimated prevalence rate of 5.6 per 100,000. The most common renal complication reported by the attending physicians was chronic kidney disease (CKD). The frequency of routine renal screening for SCD patients varied widely between centres — most were done at diagnosis, annually or bi-annually.ConclusionThe ten year prevalence of RMC in Nigerian SCD patients was determined to be 5.6 (estimated incidence of 0.56). RMC is not more common in SCD patients and therefore cannot be regarded as a “Seventh Sickle nephropathy”. Most of the managing physicians reported that the commonest nephropathy observed in their SCD patients was chronic kidney disease.     

Screening of Cyanobacterial Peptide Toxin,Microcystins in Hyperscum Water Samples from an Inland Sub Saharan Drinking Freshwater Reservoir

A study which probed the occurrence and quantitative variations hepatotoxic microcystin in a Sub Saharan drinking freshwater reservoir was carried out between November 2014 and March 2015. Results reveal the presence of MCYST-YR, MCYST-LR, MCYST-RR, MCYST-LA and MCYST-LF variants either in cells collected directly from bloom or toxic isolates cultured under laboratory conditions. Two minor microcystin congeners (MCYST-(H₄)YR) and (D-Asp³, Dha⁷) MCYST-RR) were identified, but not quantified. Variants dominance were in the order MCYST-LR?>?MCYST-RR?>?MCYST-YR?>?MCYST-LA?>?MCYST-LF across sampling sites. Maximum and minimum concentrations of quantified MCYSTs congeners were (489.25, 50.95 µg toxin/g DW), (98.92, 9.11 µg toxin/g DW), (140.25, 12.07 µg toxin/g DW), (56.99, 6.20 µg toxin/g DW) and (50.46, 3.65 µg toxin/g DW) for MCYST-LR, MCYST-YR, MCYST-RR, MCYST-LA and MCYST-LF, respectively. Analysis of variance (ANOVA) revealed there was a high significant difference between mean microcystin concentrations across sampling sites (p?<?0.05).     

Asymptomatic malaria parasitemia does not induce additional oxidative stress in pregnant women of South East Nigeria

ObjectiveTo determine the relationship between asymptomatic malaria parasitemia and some oxidative stress parameters in pregnant Nigerian women.MethodsThis is a cross-sectional study involving 130 normal pregnant women at various trimesters, who were attending antenatal clinic at the University of Nigeria Teaching Hospital (UNTH) and Kenechukwu Specialist Hospital in Enugu. A comparable group (control), made of 30 non pregnant women was also recruited. After a 24 hour dietary recall, serum levels of vitamin A, C and malondialdehyde (MDA) were determined by colorimetric method, while vitamin E was determined by absorptiometric method.ResultsThere were no statistically significant differences in age, parity, estimated calorie, vitamins A, C and E intake between the pregnant and non pregnant groups (P> 0.05). The serum level of the vitamins (umol/L) and MDA (umol/L) in control, 1st, 2nd and 3rd trimesters respectively were: (1)Vitamin A: 1.6±0.36 vs 0.6±0.26 vs 0.62± 0.33 vs 0.46± 0.21 (P < 0.0001); (2) Vitamin C: 75.65±14.15 vs 62.97±24.4 vs 37.85±15.19 vs 28.94±8.52 (P<0.0001); (3) Vitamin E: 3.01± 1.32 vs 3.45±2.01 vs 9.36±2.75 vs 9.82±2.97 (P<0.0001); (4) MDA: 1.42± 0.02 vs 1.61±0.02 vs 1.79±0.02 vs 2.03±0.05 (P<0.0001). However, there were no significant changes in the serum level of the vitamins and MDA between the positive and the negative parasitemia subjects (P>0.05).ConclusionsAsymptomatic malaria parasitemia does not induce additional oxidative stress on pregnant women in Nigeria. The enormity of acute and complicated attack should be further investigated.     

Laparoscopy for the management of early-stage endometrial cancer: from experimental to standard of care

We performed a search of PUBMED and MEDLINE for articles concerning surgical management of early stage endometrial cancer from 1950 to 2011. From the articles collected we extracted data such as estimated blood loss, operating room time, complications, conversion to laparotomy, and length of hospital stay. Forty-seven relevant sources were analyzed. The patients in the laparoscopy group had less blood loss, fewer complications, longer operating room times, and a shorter length of stay. Lymph node count was similar in both groups. Although obesity is not a contraindication to laparoscopy, it does lead to a higher conversion rate. Route of surgical treatment had no impact on recurrence or survival. Robotic surgery has significant advantages over laparotomy, but advantages over laparoscopy are not as distinct. Laparoscopic hysterectomy offers several advantages over laparotomy. These advantages relate to improvements in patient care with comparable clinical outcome. After careful analysis we believe laparoscopy should be the standard of care for surgical management of early stage endometrial cancer.     

Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience

Our aim was to evaluate the safety of transplanting kidneys from HCV‐infected donors in HCV‐uninfected recipients. Data collected from 53 recipients in a single center, observational study included donor and recipient characteristics, liver and kidney graft function, new infections and de novo donor‐specific antibodies and renal histology. Treatment with a direct‐acting antiviral regimen was initiated when HCV RNA was detected. The mean ± SD age of recipients was 53 ± 11 years, 34% were female, 19% and 79% of recipients were white and African American, respectively. The median and interquartile range (IQR) time between transplant and treatment initiation was 76 (IQR: 68‐88) days. All 53 recipients became viremic (genotype: 1a [N = 34], 1b [N = 1], 2 [N = 3], and 3 [N = 15]). The majority (81%) of recipients did not experience clinically significant increases (>3 times higher than upper limit of the normal value) in aminotransferase levels and their HCV RNA levels were in the 5 to 6 log range. One patient developed fibrosing cholestatic hepatitis with complete resolution. All recipients completed antiviral treatment and 100% were HCV RNA–negative and achieved 12‐week sustained virologic response. The estimated GFRs at end of treatment and 12‐week posttreatment were 67 ± 21 mL/min/1.73 m² and 67 ± 17 mL/min/1.73 m², respectively. Four recipients developed acute rejection. Kidney transplantation from HCV‐infected donors to HCV‐negative recipients should be considered in all eligible patients.     

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

Context  Serum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B. Objective  To evaluate the relationship between serum HBV DNA level and risk of hepatocellular carcinoma. Design, Setting, and Participants  Prospective cohort study of 3653 participants (aged 30-65 years), who were seropositive for the hepatitis B surface antigen and seronegative for antibodies against the hepatitis C virus, recruited to a community-based cancer screening program in Taiwan between 1991 and 1992. Main Outcome Measure  Incidence of hepatocellular carcinoma during follow-up examination and by data linkage with the national cancer registry and the death certification systems. Results  There were 164 incident cases of hepatocellular carcinoma and 346 deaths during a mean follow-up of 11.4 years and 41 779 person-years of follow-up. The incidence of hepatocellular carcinoma increased with serum HBV DNA level at study entry in a dose-response relationship ranging from 108 per 100 000 person-years for an HBV DNA level of less than 300 copies/mL to 1152 per 100 000 person-years for an HBV DNA level of 1 million copies/mL or greater. The corresponding cumulative incidence rates of hepatocellular carcinoma were 1.3% and 14.9%, respectively. The biological gradient of hepatocellular carcinoma by serum HBV DNA levels remained significant (P<.001) after adjustment for sex, age, cigarette smoking, alcohol consumption, serostatus for the hepatitis B e antigen (HBeAg), serum alanine aminotransferase level, and liver cirrhosis at study entry. The dose-response relationship was most prominent for participants who were seronegative for HBeAg with normal serum alanine aminotransferase levels and no liver cirrhosis at study entry. Participants with persistent elevation of serum HBV DNA level during follow-up had the highest hepatocellular carcinoma risk. Conclusion  Elevated serum HBV DNA level (10 000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.